Enrolling now · NCT06672549

A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help with weight.

What this means for you

Who can join
Children and teens 6 to 17, have obesity.
What you take
orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.3 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Eli Lilly and CompanyDrug orforglipronClass GLP-1 RASites 16 USEnrollment target 125

What this study is for

Primary condition: Obesity. Also studied in: Overweight.

Full scientific study title: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040).

Who can join

Age6 to 17SexAny

Children and teens 6 to 17, have obesity. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening.
  • Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR
  • Applies to participant age between 12 and <18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,
  • hypertension
  • type 2 diabetes (T2D)

Key exclusion criteria

  • Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:
  • gastric bypass
  • sleeve gastrectomy
  • restrictive bariatric surgery, such as Lap-Band gastric banding, or
  • any other procedure intended to result in weight reduction.

Where this study is enrolling

This trial has 16 sites across 13 states. Contact a site coordinator directly to start screening.

California1 site
  • Carey Chronis MD Pediatric, Infant and Adolescent Medicine
    Ventura, California
    805-642-4704
Connecticut2 sites
  • Yale School of Medicine - Yale Diabetes Center (YDC)) Trials
    New Haven, Connecticut
    ania.jastreboff@yale.edu
  • Stamford Therapeutics Consortium
    Stamford, Connecticut
    727-544-4842
Georgia1 site
  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics
    Atlanta, Georgia
    404-712-4731
Illinois1 site
  • Ann and Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois
    312-503-1499
Louisiana1 site
  • Velocity Clinical Research
    Lafayette, Louisiana
    337-519-4742
Mississippi1 site
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Gulfport, Mississippi
    228-206-1283
Missouri1 site
  • Sundance Clinical Research
    St Louis, Missouri
    314-567-3377
Nebraska1 site
  • Velocity Clinical Research
    Omaha, Nebraska
    402-933-6500
North Carolina1 site
  • Lucas Research, Inc
    Morehead City, North Carolina
    252-222-5700
Pennsylvania1 site
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania
    412-692-6935
Tennessee1 site
  • Vanderbilt Health One Hundred Oaks
    Nashville, Tennessee
    615-322-6000
Texas3 sites
  • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    Houston, Texas
    281-517-0550
  • La Providence Pediatrics Clinic - Chemidox Clinical Trials
    Houston, Texas
    833-324-3643
  • Martin Diagnostic Clinic
    Tomball, Texas
    281-517-0550
Utah1 site
  • Velocity Clinical Research, Salt Lake City
    West Jordan, Utah
    801-542-8190

Timeline

Started enrolling: 2024-11-18. Expected completion: 2027-03. Last updated on ClinicalTrials.gov: 2026-05-19.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.